Sacubitril/valsartan treatment is currently indicated in all symptomatic patients with heart failure with an ejection fraction ≤35% already treated with a β-blocker and an ACEi or ARB. 19 However, no ...

Conclusions Our analysis suggests that, in all three countries, sacubitril/valsartan is likely to be cost-effective compared with an ACEI (the current standard of care) in patients with HF-REF.

AT-II-receptor antagonists include losartan, valsartan, irbesartan, candesartan, eprosartan, telmisartan, and tasosartan.

Valsartan Valsartan (Diovan, Novartis) was the second nonpeptide AT-II type 1- receptor antagonist available for the treatment of hypertension. Valsartan is rapidly absorbed from the ...